Safety of Nitrate Withdrawal in Angina-Free and Hemodynamically Stable Patients with Coronary Artery Disease

Chest

Volumn 124, Issue 5, 2003, Pages 1652-1657

  George, Jacob ^a   Kitzis, Ilan ^a   Zandorf, David ^a   Golovner, Michal ^a   Shapira, Itzhak ^a   Laniado, Shlomo ^a   Roth, Arie ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Angina pectoris; Myocardial infarction; Nitrates

Indexed keywords

NITRATE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DRUG SAFETY; DRUG WITHDRAWAL; EXERCISE TEST; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEMODYNAMICS; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PATIENT COMPLIANCE; PATIENT SELECTION; PRIORITY JOURNAL; PUBLIC HOSPITAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RELAPSE; SLOW RELEASE FORMULATION; SYSTOLIC BLOOD PRESSURE;

EID: 0242468656     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.124.5.1652     Document Type: Article

References (27)

1. Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N Engl J Med 1998; 338:520-531
2. Murad F. Drugs used for the treatment of angina: organic nitrates, calcium-channel blockers, and (beta)-adrenergic antagonists. In: Gilman AG, Rall TW, Nies AS, et al, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. New York, NY: Pergamon Press, 1990; 764-783
3. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329:2002-2012
4. Loscalzo J. N-acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin. J Clin Invest 1985; 76:703-708
5. Kelly RA, Balligand JL, Smith TW. Nitric oxide and cardiac function. Circ Res 1996; 79:363-380
6. Katsuki S, Murad F. Regulation of adenosine cyclic 3′, 5′-monophosphate and guanosine cyclic 3′, 5′-monophosphate levels and contractility in bovine tracheal smooth muscle. Mol Pharmacol 1977; 13:330-341
7. Abrams J. Clinical aspects of nitrate tolerance. Eur Heart J 1991; 12(Suppl E):42-52
8. Elkayam U. Tolerance to organic nitrates: evidence, mechanisms, clinical relevance, and strategies for prevention. Ann Intern Med 1991; 114:667-677
9. DeMots H, Glasser SP. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cardiol 1989; 13:786-795
10. Parker JD, Parker AB, Farrell B, et al. Intermittent transdermal nitroglycerin therapy: decreased anginal threshold during the nitrate-free interval. Circulation 1995; 91:973-978
11. Lange RL, Reid MS, Tresch DD, et al. Nonatheromatous ischemic heart disease following withdrawal from chronic industrial nitroglycerin exposure. Circulation 1995; 91:973-978
12. Morton WE. Occupational habituation to aliphatic nitrates and the withdrawal hazards of coronary disease and hypertension. J Occup Med 1977; 19:197-200
13. Ferratini M, Pirelli S, Merlini P, et al. Intermittent transdermal nitroglycerin monotherapy in stable exercise-induced angina: a comparison with a continuous schedule. Eur Heart J 1989; 10:998-1002
14. Waters DD, Juneau M, Gossard D, et al. Limited usefulness of intermittent nitroglycerin patches in stable angina. J Am Coll Cardiol 1989; 13:421-425
15. Parker JO, Farrell B, Lahey KA, et al. Effect of intervals between doses on the development of tolerance to isosorbide dinitrate. N Engl J Med 1987; 316:1440-1444
16. Cheitlin MD, Hutter AMJ, Brindis RG, et al. ACC/AHA expert consensus document: use of sildenafil (Viagra) in patients with cardiovascular disease: American College of Cardiology/American Heart Association. J Am Coll Cardiol 1999; 33:273-282
17. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995; 345:669-685
18. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction; Gruppo Italiano per lo Studio della Sopravvivenza nel'infarto Miocardico. Lancet 1994; 343:1115-1122
19. Yusuf S, Collins R, MacMahon S, et al. Effect of intravenous nitrates on mortality in acute myocardial infarction. Lancet 1988; 1:1088-1092
20. Roth A, Kulick D, Friedenberger L, et al. Early tolerance to the hemodynamic effects of high dose transdermal nitroelycerin in responders with severe chronic heart failure. J Am Coll Cardiol 1987; 9:858-864
21. Elkayam U, Roth A, Mehra A, et al. Randomized study to evaluate the relation between oral isosorbide dinitrate dosing interval and the development of early tolerance to its effect on left ventricular filling pressure in patients with chronic heart failure. Circulation 1991; 84:2040-2048
22. Caramori PRA, Adelman AG, Azevedo ER, et al. Therapy with nitroglycerin increases coronary vasoconstriction in response to acetylcholine. J Am Coll Cardiol 1998; 32:1969-1974
23. Heitzer H, Just H, Brockhoff C, et al. Long-term nitroglycerin treatment is associated with supersensitivity to vasoconstrictors in men with stable coronary artery disease: prevention by concomitant treatment with captopril. J Am Coll Cardiol 1998; 31:83-88
24. Nakamura Y, Moss AJ, Brown MW, et al. Long-term nitrate use may be deleterious in ischemic heart disease: a study using die databases from two-large scale postinfarction studies; Multicenter Myocardial Ischemia Research Group. Am Heart J 1999; 138:577-585
25. Parker JO. Eccentric dosing with isosorbide-5-mononitrate in angina pectoris. Am J Cardiol 1993; 72:871-876
26. Parker JO, Amies MH, Hawkinson RW, et al. Intermittent transdermal nitroglycerin therapy in angina pectoris: clinically effective without tolerance or rebound; Minitran Efficacy Study Group. Circulation 1995; 91:1368-1374
27. Olsson G, Allgen J, Amtorp O, et al. Absence of pre-dose rebound phenomena with once daily 5-ISMN in a controlled-release formulation. Eur Heart J 1992; 13:814-817